Share This Author
[Aortic stenosis--angiodysplasia of the cecum].
STUDIES ON A NEW β -RECEPTOR BLOCKING DRUG: TOBANUM® (1-/2,5-DICHLOROPHENOXY/-3-TERTIARY-BUTYLAMINOPROPANOL-2-HCl). EXPERIENCES IN CARDIOVASCULAR HYPERKINETIC SYNDROME AND ANGINA PECTORIS. EFFECT ON…
[Determination of the potassium, sodium, magnesium and water content of erythrocytes].
[Hospitalization of influenza patients during epidemics].
Studies on a new beta-receptor blocking drug, tobanum--1-(2,5-dichlorophenoxy)-3-tertiary-butylamino-2-propanol HCl: its use in cardiovascular hyperkinetic syndrome, hypertension, and angina…
- I. Szám, P. Büky, A. Gulyas, M. Sinkovics
- International journal of clinical pharmacology…
- 1 March 1982
The effect of the beta-receptor blocking drug Tobanum was examined in 10 patients with idiopathic hyperkinetic heart syndrome and only in 1 case of 10 bronchitis patients and 10 healthy persons was a deterioration of vital capacity and FEV1 values found after a single dose of 2.5 mg Tobanums. Expand
The effect of the aminoketone nioben in essential circulatory hyperkinesis.